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Abstract 
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related deaths 
among female population worldwide. Metastases are the common cause of morbidity and mortality in 
breast cancer, and can remain latent for several years after surgical removal of the primary tumour. 
Thus, the identification and functional characterisation of molecular factors that promote oncogenic 
signalling in mammary tumour development and progression could provide new entry points for 
designing targeted therapeutic strategies for metastatic breast cancer. In the present study, we 
investigated the expression of proteins involved in cell signalling (GHR and NEDD9) and cell-cell 
adhesion (plakoglobin) in epithelial and stromal compartments of primary ductal invasive breast 
carcinomas and their axillary lymph node metastases versus non-metastatic tumours. Obtained data 
revealed remarkable increase in the expression levels of GHR and NEDD9 proteins in both, epithelial 
and stromal components of axillary lymph node metastases in comparison with non-metastatic 
tumours suggesting that the expression of these two proteins may provide biomarkers for tumour 
aggressiveness.  
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Introduction 
Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer-related deaths 
among female population worldwide. From the cellular, chromosomal and molecular genetics point of 
view, breast cancer is a heterogeneous disease whose management is hampered by variable response 
to treatment and differences in prognosis [1]. Traditionally, breast cancer can be classified based on 
distinctive histological features and molecular markers including histological grade, oestrogen 
receptor, progesterone receptor and HER2/ERBB2 status as well as p53 mutational status. Metastases 
are the common cause of morbidity and mortality in breast cancer and can remain latent for several 
years after surgical removal of the primary tumour [2]. In some cases, it is possible to forecast the risk 
of metastatic recurrence in breast cancer based on distinctive features of the primary lesion including 
tumour size, histological grade and gene expression signatures [3]. However, there are still many gaps 
in current understanding of genetic alterations underlying metastatic process in breast cancer, either 
locoregionally into lymph nodes or systemically into distant organs. For example, it is not clear 
whether the same genes regulate metastasis in different histologic types of breast cancer such as 
infiltrating ductal in comparison with lobular carcinoma. The advent of high-throughput technologies 
such as genome-wide expression analysis using cDNA microarray technology has offered a new 
perspective on breast cancer biology and showed that intrinsic gene expression signatures in 
combination with histopathological characteristics might prove efficient for more subtle tumour 
classification [4]. Still, these studies fail to completely delineate metastasis genetic program in breast 
cancer resulting in the proposal of negligible number of protein products with potential therapeutic 
implications in blocking metastatic progression.  
For metastasis to take place, tumour cells should detach from the primary site and penetrate through 
the vessel walls. Breakdown of the extracellular matrix (ECM) allows the cells to invade the 
surrounding tissue, enter the circulation and ultimately adhere to distant organs. In this process, cell-
cell adhesion molecules occupy a central position. Plakoglobin (also known as γ-catenin) is adhesion 
molecule found in adherens junctions and desmosomes, where it regulates cell-cell adhesion. Its 
expression has already been correlated with metastatic process in breast cancer, where plakoglobin 
seems to be involved in tumour cell shedding from the primary site into the bloodstream [5]. Down-
regulation of plakoglobin expression detected in metastatic tissues in comparison with primary 
tumours from breast cancer patients indicates that plakoglobin might play a different role in metastatic 
lesions than in primary tumours [6]. Plakoglobin has a recognised role in controlling the motility of 
epithelial cells, where its high levels are associated with lower motility and vice versa [7, 8]. More 
insights into how plakoglobin contributes to the aggressiveness of breast cancer cells were provided by 
Bailey et al. [9], who showed that metastasis regulator protein SLUG represses plakoglobin gene 
expression in the triple negative (negative in the expression of estrogen, progesterone, and ERBB2 
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receptors) breast cancer cells resulting in their increased motility. Expectedly, SLUG-negative non-
aggressive breast cancer cells expressed high levels of plakoglobin.  
Several well-known signalling pathways including the Myc, TGF-β, and Src pathways mediate some 
components of breast cancer metastasis progression [4]. In addition, there is evidence that growth 
hormone receptor (GHR)-mediated signalling pathways can be linked with the development of human 
breast cancer, possibly via autocrine or paracrine mechanisms [10]. Besides growth hormone (GH), 
other hormones could be associated with breast cancer progression including estrogen [10], whose 
biological effects are mediated by its binding to one of the structurally and functionally distinct 
oestrogen receptors. Recent study has demonstrated that estrogen negatively regulates cell spreading 
mediated by NEDD9 in human breast cancer cells giving rise to the importance of this protein in the 
breast cancer metastasis [11]. NEDD9 is involved in integrin-dependent signalling cascades which 
trigger the FAK and Src kinases responsible for cell migration, and also plays a role in Ras signalling 
cascades [12]. Growing body of evidence supports the role of NEDD9 as a tumour-promoting factor 
whose high levels in tumours correlate with poor prognosis and treatment resistance.  
The aim of this study was to evaluate the expression of proteins involved in cell signalling (GHR and 
NEDD9) and cell-cell adhesion (plakoglobin) in epithelial and stromal compartments of primary  
ductal invasive breast carcinomas and their axillary lymph node metastases in relation to their 
expression in non-metastatic tumours.   
 
Materials and methods 
Patients 
Forty tissue samples of non-metastatic (Group I) and  metastatic invasive ductal carcinoma (Group 
IIA) along with their corresponding axillary lymph node metastases (Group IIB) obtained upon 
surgical resection and confirmed by standard immunohistochemical staining methods were analysed in 
the present study. Tissue samples were obtained during regular surgery at the Sestre milosrdnice 
Clinical Hospital Center in Zagreb, Croatia. All tumour tissue samples were of G2 grade. 
Clinicopathological features of patients enrolled in this study are presented in Table 1. This study was 
approved by the Hospital’s Ethics Committee. .  
Immunohistochemistry 
Immunohistochemical analyses were performed using formalin-fixed, paraffin-embedded tissue 
sections (thickness 5 µm). After deparaffinization, tissue sections were stained by standard 
hematoxylin-eosin procedure. Deparaffinization and immunohistochemical staining were carried out 
following microwave streptavidin immunoperoxidase (MSIP) protocol and by use of labelled 
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streptavidin-biotin (LSAB) method on DAKO TechMateTM Horizon automated immunostainer. 
Monoclonal antibodies raised against estrogen receptor, progesterone receptor and HER2 (Dako, 
Denmark), growth hormone receptor (DAKO, Denmark), plakoglobin (Abcam, UK) and NEDD9 
(Abcam, UK) were used. Immunoreactivity reactions were determined in stromal and epithelial 
tumour components, as well as in stromal and epithelial components of metastatic tumours in lymph 
nodes. Epithelial and stromal reactions were determined at the site of strongest activity («hot spot») 
under magnification of 400X for a total of 1000 tumour cells. The «hot spot» was established upon the 
whole section inspection (magnification of 40X). The results were presented semi-quantitatively by 
determination of immunohistochemical staining index by taking into account the intensity of reaction 
and upon calculation of cells with positive reaction.  The intensity of the reaction was scored in the 
following way: 0, for no reaction; 1, for weak reaction; 2, for moderate to strong reaction; and 3, for 
very strong reaction. The percentage of immunoreactive (positive) tumour cells was scored as follows:  
0, for no reaction; 1, for weak reaction (up to 10% of positive cells); 2, for moderate reaction (more 
than 10-25% of positive cells); and  3, for strong reaction (over 25% of positive cells).  
Cell culture, cell substrate attachment and spreading assays  
Cell culture 
Freshly collected tissue from the surgical resection of mammary gland (Invasive ductal carcinomas 
with distant metastases HGH+ and HGH-) of the enrolled patients were minced and dispersed by 
discontinuous incubation with neutral protease (Boehringer Meinheim, Germany) and collagenase 
(Flow Laboratories L.A., CA, USA). For single cell experiments, freshly isolated cells were cultured 
at density of 3x104 cells/cm2 in tissue culture flasks (Falcon Becton Dickinson, Oxnard, CA, USA).  
The method for cultivation  of primary human tumour cells and their characterization was performed 
as described previously [13]. In brief, primary breast cancer cells cultured in 24-well plates were 
maintained in RPMI supplemented with 10% fetal bovine serum (FBS,Gibco), 2mM L-glutamine, 100 
U/ml penicillin and 100 µg/ml streptomycin in a humidified atmosphere with 5% CO2 at 37˚C 
followed by serum deprivation for 12h. Two  primary mammary carcinoma cell cultures were studied: 
growth hormone positive cells (HGH+), growth hormone negative cells (HGH-) as described 
previously [14]. Cells were washed in phosphate buffered saline (PBS), detached in Ca2+ and Mg2+ 
free PBS-based cell dissociation buffer and collected by centrifugation at 300g for 10 min (Eppendorf, 
Germany). Cells were re-suspended in the serum-free medium and plated in a crosswise mixing 
movement on the extracellular matrix to a final concentration of 1 x 104 cells in a total volume of 2 mL 
and incubated for 30, 60, 120 and 240 minutes. The medium was gently aspirated upon each treatment 
and the cells were rinsed twice in the fresh serum free medium to remove unattached cell. The 
experiment has been repeated in three biological replicates. When suspensions of single breast cancer 
cells were allowed to adhere to collagen-coated dishes they initially attached as phase-bright rounded 
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cells and then spread to form phase-dark epitheloid cells. The number of attached cells was counted 
under a light microscope. Data are expressed as the mean number of cells per grid field and 10 grid 
fields were counted for each sample. For statistical analysis the ANOVA test was performed and 
differences were considered statistically significant if p<0.05. 
Cell spreading was also assessed as the percentage of total number of attached cells by counting the 
number of cells that possessed a ‘spread morphology’ (epitheloid with lamelloid extensions) in each 
microscope field. Spreading cells (with lamelloid extensions during the spreading), came into contact 
with each other and remained in association as groups of epithelioid cells. Cell aggregates incubated in 
control medium with HGH showed a characteristic sequence of morphological changes as they were 
spreading. Cell spreading from aggregates included and orderly sequence of morphological changes: 
(1) appearance of cells at the margins of aggregates, (2) formation of monolayer patches and (3) 
eventual formation of confluent patches (monolayer patch). Spread cells were expressed as the 
proportion of total cells attached in each respective microscope field. 
 
Statistical analysis. Statistical analyses were performed using specialised software for statistical 
analysis MedCalc (MedCalc Inc., Mariakerke, Belgium) and Statistica (v. 7.0). For differential 
expression analysis, Chi-square test and ANOVA (p<0,05) were used. Post hoc analysis was 
conducted by t-test between proportions.  Differences were considered statistically significant if 
p<0.05. 
Results  
Immunohistochemical analyses of the expression of epithelial and stromal growth hormone receptor in 
non-metastatic (I), metastatic breast cancer (IIA) and corresponding axillary lymph node metastasis 
(IIB). 
 GHR expression in tissues derived from group I breast cancer, IIA and IIB are shown in Figure 1A 
and supplementary table 1,2 and 3. Weak cytoplasmic immunostaining of the epithelial component 
and moderate stromal staining for GHR in Group I tumours and strong epithelial and stromal staining 
in group IIA were detected (Figure 1A, left and middle). GHR expression was markedly increased in 
group IIB in comparison with group I in both, epithelial and stromal compartments (Chi-Square Test; 
P=0,001) (Figure 3). In stromal compartment, we detected strong and moderate staining reactions in 
47.5% cases of Group I tumours vs. 75% group IIB (figure IA right).  Interestingly, in epithelial 
compartment, we observed neither strong nor moderate reaction for GHR in Group I as opposed to 
12.5% (Group IIB, figure IA right) and 10% (Group IIA). Furthermore, there was statistically 
significant difference in GHR expression in tumours without metastases between epithelial and 
stromal compartments (Chi-Square Test; P<0.001). Its expression was increased in stroma in 
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comparison with epithelium (strong reaction: 25% vs. 0%, respectively; P=0.001; moderate reaction: 
22.5% vs. 0%, respectively; P=0.032) (Supplementary Table 1). In metastatic tumours, statistically 
significant reduction in epithelial GHR expression in comparison with its expression in stroma was 
observed (strong reaction: 7.5% vs. 30%, respectively; P=0.012) (Supplementary Table 2). Similarly, 
there was statistically relevant decline in GHR expression in epithelium in relation to stroma in 
axillary lymph node metastases (strong reaction: 7.5% vs. 47.5%, respectively; P<0.001) 
(Supplementary Table 3). Finally, no correlation was found between epithelial and stromal GHR 
expression and clinicopathological parameters including tumour size and grade, oestrogen and 
progesterone receptors status, HER-2 status and the TNM classification (data not shown).   
 
Immunohistochemical analyses of the expression of epithelial and stromal NEDD9 protein in non-
metastatic (I), metastatic breast cancer (IIA) and corresponding  axillary lymph node metastasis (IIB). 
 
Immunohistochemical staining of breast cancer tissues for NEDD9 is shown in Figure 1B. Strong 
 immunostaining of the epithelial component of  group I tumours and group IIA breast cancers was 
observed for NEDD9. There was no statistically significant difference in epithelial and stromal 
NEDD9 expression between groups I and IIA. However, the expression of NEDD9 was markedly 
increased in group IIB in comparison with group I in epithelial compartment (Chi-Square Test; P = X). 
There was strong and moderate epithelial staining reaction in 77.4% of cases (Group I) vs. 100% in 
Group IIB and 80.0% in Group IIA) (Figure 1B). Interestingly, strong staining reaction for NEDD9 
was also observed in 5% of group IIB cases  in stromal component, whereas group I and IIA showed 
either absence or weak staining reaction for stromal NEDD9 (Figure 1B). NEDD9 expression was 
predominantly detected in epithelial compartment of group I and group IIA in comparison with their 
stroma as evident from strong reaction in 67.4% vs. 0% of cases (P<0.001) and 80% vs. 0% of cases 
(P<0.001), respectively (Supplementary Tables 1 and 2). Similarly, statistically significant difference 
in NEDD9 expression between epithelial and stromal compartments in group IIB was noticed as 
inferred from strong reaction in 90% vs. 5% of all cases, respectively (P<0.001) (Supplementary Table 
3). 
 
Immunohistochemical analyses of the expression of epithelial and stromal plakoglobin in non-
metastatic (I), metastatic breast cancer (IIA) and corresponding axillary lymph node metastasis (IIB). 
Immunohistochemical staining of breast cancer tissues for plakoglobin is shown in Figure 1C. In 
general, strong immunostaining of the epithelial component and negative or weak stromal staining was 
observed in groups I and IIA. Similarly, immunohistochemical detection revealed strong cytoplasmic 
immunostaining of the epithelial component in group IIB (figure 1C). Plakoglobin expression was 
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significantly increased in epithelial compartment of group IIA and IIB tumours in comparison with 
group I tumours as evident from strong and moderate staining reactions observed in 92.5% (Group 
IIA) and 87.5% (Group IIB) cases, respectively vs. 65% in Group I tumours (Figure 1C, Figure 3). 
Interestingly, either complete absence or only weak staining of plakoglobin was detected in stromal 
components of all tissue samples (figure 1C).  A tendency toward a decrease in plakoglobin expression 
in epithelial component of nodal metastases in comparison with the corresponding primary tumour 
could be noticed. In addition, there was statistically significant increase in plakoglobin expression in 
epithelium in comparison with stroma in non-metastatic (strong reaction: 65% vs. 0%, respectively; 
P<0.001) and metastatic tumours (strong reaction: 85% vs. 0%, respectively; P<0.001) as well as in 
axillary lymph node metastases (strong reaction: 87.5% vs 0%, respectively; P<0.001) (Supplementary 
Tables 1-3).  Interestingly, expression of plakoglobin was significantly higher in Group I tumours in 
comparison with Group IIB (p<0,02). 
Cell substrate attachment and spreading assay 
The relation between HGH expression and the spreading ability of cells in culture was assessed. The 
ability to spread upon adhesive substrate is a characteristic feature of many cultured cells. Cell 
spreading reflects the adhesive interaction between cells and their substrate. Changes in cell substrate 
adhesion may contribute to cell aggregation, in a complex sequence of changes from adsorption of 
cells to substrate, attachment (where they become resistant to shear forces) and eventually spreading. 
These changes normally form a continuous process in culture, but can be experimentally separated and 
are likely to be mediated by different adhesive mechanisms [13]. Whereas the spreading of single cells 
primarily reflects cell-substrate adhesion, spreading of cells from aggregates is likely to be influenced 
by the balance between cell-cell and cell substrate adhesion as well. Thus, stimulation of cell-cell 
adhesion by HGH is predicted to shift the balance of adhesive forces acting upon the cells to favour 
aggregation [14]. Conversely, a decrease in cell-cell adhesion may alter that adhesive balance 
sufficiently to cause cell spreading without any concomitant change in cell adhesiveness for substrate. 
For that purpose, single cells were incubated in ECM alone or in serum free medium supplemented 
with 100 nM HGH. After the incubation, wells were washed to remove non-attached cells. Cell 
attachment (cells per field) and cell spreading (% of the total number of attached cells) were measured 
and presented as a mean + SD. The cell substrate attachment and spreading assay results confirmed 
observed immunohistochemical data (Table 2. Figure 2). The HGH positive cells showed higher 
attachment rates in comparison with HGH negative cells ranging between 14 and 32%. The lowest 
attachment rate was observed upon 30 minutes of treatment with HGH and diminished with increased 
incubation time. However, treatment of HGH negative cells with HGH reversed the attachment rates 
to normal.  
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Similar results were obtained for cell spreading assay, where spreading rates for HGH positive cells in 
comparison with HGH negative cells ranged between 19 and 48% (Figure 2). Again, treatment of 
HGH negative cells with HGH reversed the spreading rates to normal. When suspensions of single 
breast cancer cells were allowed to adhere to collagen-coated dishes they initially attached as phase-
bright rounded cells and then spread to form phase-dark epitheloid cells (with lamelloid extensions 
during the spreading). This change in morphology was accompanied by increased spreading.  A 
similar effect was observed by Gabriele Handschuh et al. [15] where mammary carcinoma cell line 
bearing mutant E-cadherin showed an increased cell motility which was accompanied with 
morphological changes including epitheloid morphology. 
Discussion 
Taking into account high mortality rates associated with metastatic breast cancer, the identification 
and functional characterisation of cellular and molecular factors driving breast cancer invasion and 
metastasis are of major health significance. Several experimental studies and clinical observations 
have brought into focus the possible role of pituitary hormones including growth hormone (GH) and 
its receptor (GHR) in human breast carcinogenesis. It has been found that expression of GHR in tumor 
cells might be increased due to autocrine stimulation [16] and that more than 50% of all breast cancer 
cases stain positively for GHR [17]. Kovari et al indeed, shown that positive staining for the GHR was 
more frequent in grade 2 tumours (86%), in comparison with grade 1 (18%) or grade 3 (47%) cancers. 
Moreover, Gebre-Medhin et al. [10] analysed 48 human breast carcinomas and 17 adjacent normal 
breast tissues to establish the expression status of GHR, and found that GHR expression was up-
regulated in breast cancer compared to adjacent normal breast tissue. GHR was predominantly 
expressed within the epithelial compartment of tumours, and its expression was detected in some 
stromal cells of the breast carcinoma as well. Our study showed remarkable increase in GHR 
expression in both, epithelial and stromal components of axillary lymph node metastases in 
comparison with non-metastatic tumours and normal breast tissue (data not shown) indicating that 
deregulation of GHR expression might be associated with the development of metastases in breast 
cancer (Figures 1-3). However, several similar studies do not completely support the correlation 
between the GHR expression status and breast cancer progression. For example, Mertani et al. [20] 
detected GHR expression in epithelial cells of normal, benign proliferative breast disease 
(fibroadenoma, papilloma, adenosis, epitheliosis) and neoplastic lesions of the breast (intraductal 
carcinoma or lobular carcinoma in situ, and invasive ductal, lobular or medullary carcinoma), and 
concluded that the putative role of GH in the progression of proliferative mammary disorders cannot 
be ascribed to major alterations in the GHR expression levels. Similarly, Gebre-Medhin et al. [10] 
postulated that increased GHR expression does not correspond to aggressive biological behaviour per 
se based on an inverse correlation found between GHR expression and proliferative activity and 
tumour grade, and GHR expression detected in both, stromal and epithelial cells of a benign phyllodes 
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tumour [10]. However, if epithelial expression of GHR was compared with plakoglobin and NEDD9 
in specific histological types, GHR expression was significantly lower (p<0,0001) in comparison in 
the Luminal A, Luminal B histological types and HER2+ subtype (Supplementary figure 1). 
Moreover, the patients survival rates were significantly higher for the group of non-metastatic tumours 
in comparison with metastatic tumours and HER2+ subtype (Supplementary Figure 2). Due to 
inconsistent data published in the literature so far, we might postulate that expression of GHR cannot 
be used as a sole marker for tumour aggressiveness and invasiveness but might be used in addition to 
standard immunohistochemical data and other markers, i.e. plakoglobin and NEDD9 as substantiated 
by presented results.  
Plakoglobin is a member of the Armadillo protein family, and is a structural and functional homolog 
of β-catenin involved in the regulation of cell-cell adhesion and cell signalling [21]. Several studies 
reported on the association between decreased plakoglobin expression and increased invasive 
behaviour of breast cancer cells proposing its possible clinical utility as potential prognostic factor of 
increased risk of breast cancer progression and as a therapeutic target [22], [23,24, 5]. For example, 
Mukhina et al. [25] showed that autocrine production of GH in human mammary carcinoma cells 
specifically reduced the expression of plakoglobin associated with relocalization of E-cadherin to the 
cytoplasm, disruption of cell-cell contacts and altered cellular morphology and motility. This 
decreased plakoglobin expression triggered by autocrine GH was indispensable for acquisition of an 
invasive phenotype in human mammary carcinoma cells, as forced expression of plakoglobin in 
human mammary carcinoma cell line MCF-7 stably transfected with the GH gene greatly reduced 
invasive capacity of these cells [25]. Presented in vitro results support the role of human GH in 
increased motility of primary breast cancer cells as well where human GH negative cells treated with 
human GH increasingly spread in culture (Table 2, Figure 2). Moreover, Holen et al. [5] showed that 
reducing expression of plakoglobin in human breast cancer cell lines increases cell motility and 
invasion and reduces cell-cell adhesion. In addition, these authors found very low levels of 
plakoglobin in the highly metastatic breast cancer cell lines, higher levels of plakoglobin in weakly 
metastatic cells and very high levels in non-metastatic cells providing evidence that reduced 
plakoglobin expression increases the metastatic phenotype of breast cancer cells.  
These in vitro results support a tumour suppressor role for plakoglobin, previously described in the 
lietaruture, i.e. through inhibition of the c-Myc gene expression [26] or indirectly, through regulation 
of tumour suppressor genes expression, including PML in renal cells [27] and modulation of the 
cytoskeleton and RhoGTPase signalization [28]. Indeed, several independent clinical examinations of 
plakoglobin expression patterns in primary breast carcinoma detected reduced expression of 
plakoglobin [23], [24], [29], [30]. Importantly, invasive ductal carcinomas showed statistically 
signiﬁcant higher expression of plakoglobin in the metastases in comparison with corresponding 
primary tumours, as supported by our results as well, whereas in invasive lobular carcinoma there was 
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no statistically different expression in the metastatic lesions compared with those in the corresponding 
primary tumours [23]. On the contrary, Bukholm et al. [6] reported on down-regulation of plakoglobin 
in metastatic lesions from invasive ductal carcinoma in comparison with the primary tumour. Results 
presented in the current study revealed statistically significant increase in plakoglobin expression in 
the epithelial compartment of primary metastatic breast cancer tissues in comparison with non-
metastatic tumours indicating that plakoglobin in metastatic breast carcinomas might bear a biological 
function different from that in benign breast tumours. Indeed, literature evidence supports both the 
tumour suppressive and oncogenic roles of plakoglobin. The oncogenic activity of plakoglobin, as 
observed in presented study as well, may be a results of modulation of the protein levels and signalling 
ability of β-catenin [31, 32]. 
A growing line of evidence supports the role of NEDD9/HEF1/Cas-L, a member of the Cas family of 
adhesion docking molecules, in breast cancer progression. In vitro studies showed that overproduction 
of HEF1 in MCF7 breast carcinoma cells promotes cell spreading and migration, and increases levels 
of mRNA transcripts encoding proteins that are associated with motility, cell transformation and 
invasiveness [33]. The first in vivo evidence linking NEDD9 with breast cancer aggressiveness came 
from the study demonstrating that genetic deletion of NEDD9 signiﬁcantly limits early tumour 
development and diminishes cell spreading and migration  in a mouse model of mammary tumour 
development [34]. Lack of NEDD9 caused marked down-regulation of pro-oncogenic signalling 
pathways including AKT, Src, FAK, and ERK in the late-appearing Nedd9(-/-) tumours, pointing to 
the role of Nedd9 as a scaffolding protein for these proteins. Further elucidation of the role of NEDD9 
in breast cancer progression was provided by Kong et al. [35] who showed that NEDD9 activates 
epithelial-mesenchymal transition, as overexpression of NEDD9 in human mammary epithelial cells 
led to the reduction of the epithelial markers with concomitant increase in the mesenchymal markers, 
and promoted cell migration and invasion. Additionally, inhibition of endogenous NEDD9 expression 
in highly aggressive triple-negative breast cancer (TNBC) cell lines reduced the migration, invasion 
and proliferation of these cells and partially reversed the EMT process. Immunohistochemical analysis 
of mammary tissue sections from breast cancer patients showed increased expression of NEDD9 in 
breast carcinoma cells in comparison with normal mammary epithelial cells. Importantly, high levels 
of NEDD9 expression were associated with the aggressive breast cancers, including TNBC and 
ERBB2-positive subtypes [35]. Our results also support the role of NEDD9 as metastasis marker in 
breast cancer, as we observed significant rise in NEDD9 expression in both, epithelial and stromal 
components of axillary lymph node metastases in comparison with their corresponding primary 
tumours. In light of the finding that absence of NEDD9 greatly sensitizes cells to the Src-family 
targeting agent dasatinib clinically used for treatment of breast and other cancers [12], 
pharmacological inhibition of NEDD9-mediated signalling pathways might provide an entry point for 
the development of novel therapeutic strategies for treating metastatic breast cancer.  
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In conclusion, our study revealed remarkable increase in the expression levels of GHR and NEDD9 
proteins in both, epithelial and stromal components of axillary lymph node metastases in comparison 
with non-metastatic tumours suggesting that the expression of these two proteins may provide 
biomarkers for breast cancer aggressiveness. In addition, reduced expression of epithelial plakoglobin 
in nodal metastases in comparison with primary  ductal invasive breast carcinomas indicates that 
deregulation of plakoglobin expression might play a critical role in the acquisition of an invasive 
phenotype in human mammary carcinoma cells.   
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Tables 
Table 1. Clinical and pathological data for breast cancer patients enrolled in the presented study with 
(N1,MX and N2MX) or without metastases in axillary lymph nodes (N0, Mx). 
 
Clinical/Pathological 
parameters 
Non-metastatic tumors 
No. (%) 
Metastatic tumors 
No. (%) 
Age (years)   
<40 1 (2.5) 3 (7.5) 
>40-60 21 (52.5) 18 (45.0) 
>60-80 16 (40.0) 16 (40.0) 
>80 2 (5) 3 (7.5) 
Tumor size (cm)   
< 2 28 (70.0) 14 (35.0) 
> 2-5 12 (30.0) 21 (52.5) 
> 5 - 5 (12.5) 
ER status   
Negative reaction 9 (22.5) 8 (20.0) 
Weak reaction 0 (0) 8 (20.0) 
Moderate reaction 6 (15.0) 1 (2.5) 
Strong reaction 25 (62.5) 23 (57.5) 
PR Status   
Negative reaction 10 (25.0) 10 (25,0) 
Weak reaction 0 (0) 5 (12.5) 
Moderate reaction 10 (25.0) 3 (7.5) 
Strong reaction 20 (50.0) 22 (55.0) 
HER 2 Status   
Negative reaction (-) 18 (45.0) 30 (75.0) 
Weak reaction (+) 6 (15.0) 0 (0) 
Moderate reaction (++) 7 (17.5) 2 (5.0) 
Positive reaction (+++) 9 (22.5) 8 (20.0) 
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Table 2. Results of the cell attachment and cell spreading assays presented as percentage of attached 
cells or total spreading ± standard deviation. HGH; human growth hormone.  
Time 
(minutes) 
Percentage of attached cells (%) Percentage of total cell spreading (%) 
HGH + HGH - 
HGH treated  
with HGH 
HGH + HGH - 
HGH 
treated  
with HGH 
30 78.4±6.9 46.1±8.4 73.8±4.7 61.7±7.2 13.6±3.7 57.2±6.9 
60 85.8±4.4 64.4±7.2 84.8±5.3 83.7±9.1 40.8±9.6 82.0±6.8 
120 91.6±4.4 77.4±7.3 91.3±7.2 90.1±9.9 58.7±6.2 87.6±8.2 
240 100.0 84.0±11.2 100.0 100.0 80.2±12 100.0 
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Figures 
 
 
 
Figure 1. Immunohistochemical staining of GHR (A), NEDD9 (B) and plakoglobin (C) in non-
metastatic tumours (group I, left), tumours with axillary lymph node metastases (group IIA, middle), 
and axillary lymph node metastases (group IIB, right). (All photos x200) 
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Figure 2. Cell attachment assay (upper panel) and cell spreading assay (lower panel). Isolated primary 
single breast cancer cells were cultured in collagen-coated dishes. After varying periods of time dishes 
were washed to remove non adherent cells. Cell attachment (cells per field) and cell spreading (% of 
total number of attached cells) were measured and data are presented as mean ± SD.   
20 
 
 
Figure 3. Percentage of positive reactions for GHR, NEDD9 and plakoglobin in the epithelial and 
stromal tumour components. Statistically significant differences between the epithelial and stromal 
component (p<0.05) were obtained at strong and moderate expression for all tested markers. 
 
21 
 
Supplementary Table 1. Non-metastatic tumours: Expression of NEDD9, plakoglobin, and growth 
hormone receptor (GHR) in the epithelial and stromal tumour component  
 
 
 
Presence N / % 
Statistics 
 
Epithelial 
component 
(n=40) 
Stromal 
component 
(n=40) 
post-hoc 
NEDD9 
No reaction 8  (20.0) 28 (70.0) 
χ2=51.4 
P<0.001* 
 
Weak reaction 1  (2.6) 12 (30.0)  
Moderate reaction 4 (10.0) 0  
Strong reaction 27 (67.4) 0 P<0.001* 
PLAKOGLOBIN 
No reaction 14 (35.0)  30 (75.0) 
χ2=41.8 
P<0.001* 
 
Weak reaction 0 10 (25.0)    
Moderate reaction 0 0  
Strong reaction 26 (65.0) 0 P<0.001* 
GHR 
No reaction 26 (65.0) 9 (22.5) 
χ2=27.4 
P<0.001* 
 
Weak reaction 14 (35.0)  12 (30.0)  
Moderate reaction 0 9 (22.5) P=0.032* 
Strong reaction 0 10 (25.0)   P=0.001* 
*
statistically significant
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Supplementary Table 2. Tumours with axillary lymph nodes metastases: Expression of NEDD9, 
plakoglobin and growth hormone receptor (GHR) in the epithelial and stromal tumour component. 
 Presence N / %  
 
Statistics 
 
 
Epithelial 
component 
(n=40) 
Stromal 
component 
(n=40) 
 
post-hoc 
NEDD9 
No reaction 8 (20.0) 22 (55.0)  
χ2=56.5 
P<0.001* 
 
Weak reaction 0 18 (45.0)   
Moderate reaction 0 0  
Strong reaction 32 (80.0) 0 P<0.001* 
PLAKOGLOBIN 
No reaction 0 35 (87.5) 
χ2=82.5 
P<0.001* 
 
Weak reaction 3 (7.5)  5 (12.5)   
Moderate reaction 3 (7.5)  0  
Strong reaction 34 (85.0) 0 P<0.001* 
GHR 
No reaction 21 (52.5) 13 (32.5) 
χ2=10.9 
P=0.012* 
 
Weak reaction 15 (37.5) 10 (25.0)  
Moderate reaction 1 (2.5) 5 (12.5)  
Strong reaction 3 (7.5)  12 (30.0) P=0.012* 
*
 statistically significant
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Supplementary Table 3. Metastatic axillary lymph nodes: Expression of NEDD9, plakoglobin and 
growth hormone receptor (GHR) in the epithelial and stromal tumour component. 
 Presence N / %  
 
Statistics 
 
 
Epithelial 
component 
(n=40) 
Stromal 
component 
(n=40) 
 
post-hoc 
NEDD9 
No reaction 0 18 (45.0) 
χ2=72.4 
P<0.001* 
 
Weak reaction 0 20 (50.0)  
Moderate reaction 4 (10.0) 0  
Strong reaction 36 (90.0) 2 (5,0) P<0.001* 
PLAKOGLOBIN 
No reaction 5 (12.5) 31 (77.5) 
χ2=62.8 
P<0.001* 
 
Weak reaction 0 9 (22.5)   
Moderate reaction 0 0  
Strong reaction 35 (87.5) 0 P<0.001* 
GHR 
No reaction 0 0 
χ2=31.8 
P<0.001* 
 
Weak reaction 35 (87.5) 10 (25.0)  
Moderate reaction 2 (5.0) 11 (27.5)  
Strong reaction 3 (7.5) 19 (47.5) P<0.001* 
*
 statistically significant
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Supplementary Figure 1. Statistically significant differences were observed: in the stromal 
expression of PLAKOGLOBIN in comparison with GHR and NEDD9 (lower expression at 
p<0,0001) (Panel A) 
in the epithelial expression of GHR (lower expression at p<0,0001) in comparison with 
PLAKOGLOBIN and NEDD9 for the Luminal A, Luminal B histological types and HER2+ subtype 
(Panel B). 
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Supplementary Figure 2. The Kaplan-Meier analysis of survival rates in days for different 
histological tumor types show a significant reduction in survival for the HER2 positive tumours in 
comparison with Luminal A and B tumours (χ2 = 15,2781; p = 0,018). The result for triple negative 
tumours should be interpreted cautiously due to the small sample number (n=1). 
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